Atossa Therapeutics (ATOS) 10-Q 9 May 22 2022 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 06, 2022
Document Information [Line Items]
Entity Central Index Key	0001488039
Entity Registrant Name	ATOSSA THERAPEUTICS, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-35610
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-4753208
Entity Address, Address Line One	107 Spring Street
Entity Address, Postal Zip Code	98104
Entity Address, City or Town	Seattle
Entity Address, State or Province	WA
City Area Code	206
Local Phone Number	325-6086
Title of 12(b) Security	Common Stock, $0.18 par value
Trading Symbol	ATOS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		126,624,110

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 131,486	$ 136,377
Restricted cash	110	110
Prepaid expenses	3,874	2,488
Research and development rebate receivable	668	1,072
Other current assets	710	1,193
Total current assets	136,848	141,240
Other assets	630	22
Total Assets	137,478	141,262
Current liabilities
Accounts payable	1,596	1,717
Accrued expenses	120	204
Payroll liabilities	593	1,184
Other current liabilities	13	21
Total current liabilities	2,322	3,126
Total Liabilities	2,322	3,126
Commitments and contingencies (Note 13)
Stockholders' equity
Preferred stock - $0.001 par value; 10,000 shares authorized; 1 share issued and outstanding as of March 31, 2022 and December 31, 2021	0	0
Common stock - $0.18 par value; 175,000 shares authorized; 126,624 shares issued and outstanding as of March 31, 2022 and December 31, 2021	22,792	22,792
Additional paid-in capital - common stock	245,802	243,996
Accumulated deficit	(134,020)	(129,234)
Total Stockholders' Equity	135,156	138,136
Total Liabilities and Stockholders' Equity	137,478	141,262
Series B Preferred Stock [Member]
Stockholders' equity
Additional paid-in capital - Series B convertible preferred stock	$ 582	$ 582

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares shares in Thousands	Mar. 31, 2022	Dec. 31, 2021
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	10,000	10,000
Preferred stock, issued (in shares)	1	1
Preferred stock, outstanding (in shares)	1	1
Common stock, par value (in dollars per share)	$ 0.18	$ 0.18
Common stock, authorized (in shares)	175,000	175,000
Common stock, issued (in shares)	126,624	126,624
Common stock, outstanding (in shares)	126,624	126,624

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses
Research and development	$ 1,499	$ 1,379
General and administrative	3,248	2,152
Total operating expenses	4,747	3,531
Operating loss	(4,747)	(3,531)
Other expense, net	(39)	(7)
Loss before income taxes	(4,786)	(3,538)
Income taxes	0	0
Net loss	$ (4,786)	$ (3,538)
Loss per common share - basic and diluted (in dollars per share)	$ (0.04)	$ (0.04)
Weighted average shares outstanding - basic and diluted (in shares)	126,624	92,587

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Cumulative Effect, Period of Adoption, Adjusted Balance [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]Conversion of Series B Convertible Preferred Stock into Common Stock [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Preferred Stock Additional Paid-in Capital [Member]Series B Convertible Preferred Stock [Member]Cumulative Effect, Period of Adoption, Adjusted Balance [Member]	Preferred Stock Additional Paid-in Capital [Member]Series B Convertible Preferred Stock [Member]Conversion of Series B Convertible Preferred Stock into Common Stock [Member]	Preferred Stock Additional Paid-in Capital [Member]Series B Convertible Preferred Stock [Member]	Common Stock [Member]Cumulative Effect, Period of Adoption, Adjusted Balance [Member]	Common Stock [Member]Conversion of Series B Convertible Preferred Stock into Common Stock [Member]	Common Stock [Member]	Common Stock, Additional Paid-in Capital [Member]Cumulative Effect, Period of Adoption, Adjusted Balance [Member]	Common Stock, Additional Paid-in Capital [Member]Conversion of Series B Convertible Preferred Stock into Common Stock [Member]	Common Stock, Additional Paid-in Capital [Member]	Retained Earnings [Member]Cumulative Effect, Period of Adoption, Adjusted Balance [Member]	Retained Earnings [Member]Conversion of Series B Convertible Preferred Stock into Common Stock [Member]	Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjusted Balance [Member]	Conversion of Series B Convertible Preferred Stock into Common Stock [Member]	Total
Balance (in shares) at Dec. 31, 2020			1,000						47,550,000
Balance at Dec. 31, 2020	$ 0		$ 0	$ 0		$ 621	$ 0		$ 8,559	$ 9,732		$ 129,887	$ 3,271		$ (111,899)	$ 13,003		$ 27,168
Issuance of common stock and warrants, shares (in shares)			0						41,211,000
Issuance of common stock and warrants			$ 0			0			$ 7,418			62,250			0			$ 69,668
Issuance of common stock upon warrant exercise (in shares)			0						32,063,000									32,063,000
Issuance of common stock upon warrant exercise			$ 0			0			$ 5,771			26,989			0			$ 32,760
Conversion of Series B convertible preferred stock to common stock		$ 0			$ (1)			$ 0			$ 1			$ 0			$ 0
Conversion of Series B convertible preferred stock to common stock (in shares)								0									1
Compensation cost for stock options granted			0			0			0			640			0			640
Net loss			$ 0			0			$ 0			0			(3,538)			(3,538)
Balance (in shares) at Mar. 31, 2021			1,000						120,824,000
Balance at Mar. 31, 2021			$ 0			620			$ 21,748			229,499			(112,166)			139,701
Balance (in shares) at Dec. 31, 2021			1,000						126,624,000
Balance at Dec. 31, 2021			$ 0			582			$ 22,792			243,996			(129,234)			138,136
Conversion of Series B convertible preferred stock to common stock (in shares)																	0
Compensation cost for stock options granted			0			0			0									1,806
Net loss			$ 0			0			$ 0			0						(4,786)
Balance (in shares) at Mar. 31, 2022			1,000						126,624,000
Balance at Mar. 31, 2022			$ 0			$ 582			$ 22,792			$ 245,802			$ (134,020)			$ 135,156

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Issuance costs	$ 5,493

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (4,786)	$ (3,538)
Adjustments to reconcile net loss to net cash used in operating activities
Compensation cost for stock options granted	1,806	640
Depreciation and amortization	2	9
Changes in operating assets and liabilities:
Prepaid expenses	(1,386)	(737)
Research and development rebate receivable	404	(85)
Other assets	(114)	582
Accounts payable	(121)	(866)
Accrued expenses	(84)	58
Payroll liabilities	(591)	(474)
Other current liabilities	(8)	3
Net cash used in operating activities	(4,878)	(4,408)
CASH FLOWS FROM INVESTING ACTIVITY
Purchase of furniture and equipment	(13)	0
Net cash used in investing activities	(13)	0
CASH FLOWS FROM FINANCING ACTIVITY
Proceeds from issuance of common stock, net of issuance costs	0	69,668
Proceeds from exercise of warrants	0	32,760
Net cash provided by financing activities	0	102,428
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	(4,891)	98,020
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE	136,487	39,664
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE	131,596	137,684
SUPPLEMENTAL DISCLOSURES
Cash and cash equivalents	131,486	137,574
Restricted cash	110	110
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows	131,596	137,684
NONCASH INVESTING AND FINANCING ACTIVITIES
Reclassification of the warrant liability to equity upon adoption of accounting standard	0	13,003
Conversion of Series B Convertible Preferred Stock into Common Stock [Member]
NONCASH INVESTING AND FINANCING ACTIVITIES
Conversion of Series B convertible preferred stock to common stock	$ 0	$ 1

Note 1 - Nature of Operations

Note 1 - Nature of Operations	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Nature of Operations [Text Block]	NOTE 1: Atossa Therapeutics, Inc. (the Company) was incorporated on April 30, 2009 19 December 31. Impact of the Novel Coronavirus The ongoing COVID- 19 may third H201,AT 301 19 may 19 19 may 19 not not 301 H201. 19 19 19 may 19

Note 2 - Liquidity and Capital

Note 2 - Liquidity and Capital Resources	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Liquidity and Capital Resources [Text Block]	NOTE 2: The Company has incurred net losses and negative operating cash flows since inception. For the three March 31, 2022, March 31, 2022, not 2021, one no may

Note 3 - Summary of Accounting

Note 3 - Summary of Accounting Policies	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	NOTE 3: Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions to Form 10 10 01 X. not no 10 December 31, 2021. not In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three March 31, 2022, not may December 31, 2022. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Segments The Company operates in a single segment. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. To date, our chief operating decision maker has made such decisions and assessed performance at the company level as one segment. Research and Development Research and development (R&D) costs are generally expensed as incurred. R&D expenses include, for example, manufacturing expense for the Company's drugs under development, expenses associated with clinical trials and associated salaries and benefits. The Company has entered into various research and development contracts with research institutions, clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may may R&D expenses also include an allocation of the CEO's salary and related benefits including bonus and non-cash stock-based compensation expense based on an estimate of total hours expended on research and development activities. The Company's CEO is involved in the development of the Company's drug candidates and oversight of the related clinical trial activity. Fair Value Measurements The Company records financial assets and liabilities measured on a recurring and non-recurring basis as well as all non-financial assets and liabilities subject to fair value measurement at the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. These fair value principles prioritize valuation inputs across three 1 2 3 8. Stock-based Payments The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including employee stock options. Stock compensation expense is based on the estimated grant date fair value and is recognized as an expense over the requisite service period. The Company has made a policy election to recognize forfeitures when they occur. The fair value of each option grant is estimated using the Black-Scholes option-pricing model, which requires assumptions regarding the expected volatility of the stock options, the expected life of the options, an expectation regarding future dividends on the Company’s common stock, and estimation of an appropriate risk-free interest rate. The Company’s expected common stock price volatility assumption is based upon the historical volatility of our stock price. The Company has elected the simplified method for the expected life assumption for stock option grants, which averages the contractual term of the options of ten one four not no Recently Adopted Accounting Pronouncements On May 3, 2021, No. 2021 04, Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options no March 31, 2022, not On January 1, 2022, 2021 10 Annual Disclosure Requirements for Business Entities Receiving Government Assistance. (Topic 832 Disclosures by Business Entities about Government Assistance 6.

Note 4 - Restricted Cash

Note 4 - Restricted Cash	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Restricted Assets Disclosure [Text Block]	NOTE 4: The Company's restricted cash balance of $110 as of March 31, 2022 December 31, 2021,

Note 5 - Prepaid Expenses

Note 5 - Prepaid Expenses	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Prepaid Expenses [Text Block]	NOTE 5: Prepaid expenses consisted of the following: As of March 31, As of December 31, 2022 2021 Prepaid research and development $ 2,927 $ 1,853 Prepaid insurance 613 461 Professional services 293 124 Other 41 50 Total prepaid expenses $ 3,874 $ 2,488

Note 6 - Research and Developme

Note 6 - Research and Development Rebate Receivable	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Research and Development Tax Rebate Receivable [Text Block]	NOTE 6: On May 23, 2017, 1 2 19 $0.435 four 20 three March 31, 2022 2021, March 31, 2022 December 31, 2021, March 31, 2022 December 31, 2021, three March 31, 2022 2021, The Company had realized (losses) and gains on foreign currency exchange, related to the research and development rebate receivable balance, during the three March 31, 2022 March 31, 2021,

Note 7 - Payroll Liabilities

Note 7 - Payroll Liabilities	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	NOTE 7: Payroll liabilities consisted of the following: March 31, December 31, 2022 2021 Accrued bonuses $ 241 $ 894 Accrued vacation 229 183 Accrued payroll 123 107 Total payroll liabilities $ 593 $ 1,184

Note 8 - Fair Value of Financia

Note 8 - Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 8: Pursuant to the accounting guidance for fair value measurement and its subsequent updates, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date. The accounting guidance establishes a hierarchy for inputs used in measuring fair value that minimizes the use of unobservable inputs by requiring the use of observable market data when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on active market data. Unobservable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances. The fair value hierarchy is broken down into the three ● Level 1 1 ● Level 2 2 ● Level 3 no The following tables present the Company’s fair value hierarchy for all its financial assets and liabilities, by major security type, measured at fair value on a recurring basis: March 31, 2022 Estimated Fair Value Level 1 Level 2 Level 3 Assets: Money market account $ 51,797 $ 51,797 $ - $ - December 31, 2021 Estimated Fair Value Level 1 Level 2 Level 3 Assets: Money market account $ 51,796 $ 51,796 $ - $ - Warrants issued in December 2020 may not not 3 January 1, 2021, No. 2020 06, Debt Debt with Conversion and Other Options (Topic 470 (Topic 815 The following table summarizes the changes in the Company’s Level 3 three March 31, 2021: Warrant liability Beginning balance $ 13,003 Reclassification of equity upon adoption of accounting standard (13,003 ) Issuance of warrants - Change in fair value - Ending balance $ -

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 9: EQUITY The Company is authorized to issue a total of 185,000 shares of stock consisting of 175,000 shares of common stock, par value $0.18 per share, and 10,000 shares of preferred stock, par value $0.001 per share. The Company has designated 750 shares of Series A junior participating preferred stock, par value $0.001 per share, 4 shares of Series A convertible preferred stock, par value $0.001 per share, 25 shares of Series B convertible preferred stock, par value $0.001 and 20 shares of Series C convertible preferred stock, par value $0.001 per share, through the filings of certificates of designation with the Delaware Secretary of State. No shares of Series A junior participating preferred stock, no shares of Series A convertible preferred stock and no shares of Series C convertible preferred stock are outstanding as of March 31, 2022 December 31, 2021. 2021 On January 6, 2021, one 1933, January 8, 2021 On March 22, 2021, one 0.75 3 No. 333 255411 April 29, 2021. Series B Convertible Preferred Stock Conversion. first not Fundamental Transactions. Dividends. Voting Rights. no Liquidation Preference . Redemption Rights. not not Warrants The terms and conditions of the warrants are as follows: Exercisability 4 The number of shares of common stock issuable upon exercise of the warrants is subject to adjustment in certain circumstances, including a stock split, stock dividend on, or a subdivision, combination or recapitalization of the common stock. Upon the merger, consolidation, sale of substantially all of our assets, or other similar transaction, the holders of warrants shall, at the option of the Company, be required to exercise the warrants immediately prior to the closing of the transaction, or such warrants shall automatically expire. Upon such exercise, the holders of warrants shall participate on the same basis as the holders of common stock in connection with the transaction. Cashless Exercise no not may Exercise Price one not may no Transferability may may Exchange Listing not Rights as Stockholder not Warrants Outstanding As of March 31, 2022, Outstanding Warrants to Purchase Shares Exercise Price Per Share Expiration date May 2018 warrants 762 $ 4.05 May 30, 2022 December 2020 warrants 6,490 $ 1.00 December 11 2024-June 21, 2025 January 2021 warrants 4,500 $ 1.055 July 8, 2025 March 2021 warrants 10,525 $ 2.88 September 22, 2025 22,277 Warrant Activity There were no warrant exercises during the three March 31, 2022. three March 31, 2021, Conversion of Convertible Preferred Stock During the three March 31, 2022, three March 31, 2021,

Note 10 - Net Loss Per Share

Note 10 - Net Loss Per Share	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 10: The Company follows the two two two Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. In addition, in computing the dilutive effect of convertible securities, the numerator is adjusted to add back any convertible preferred dividends. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of potential future exercises of outstanding stock options and common stock warrants. Because the inclusion of potential common shares would be anti-dilutive for all periods presented, they have been excluded from the calculation. The Company’s warrants and preferred stock contractually entitles the holders of such securities to participate in dividends but do not not not March 31, 2022, 2021. The following table summarizes the Company’s calculation of net loss per common share: Three Months Ended March 31, 2022 2021 Numerator Net loss attributable to common shareholders $ (4,786 ) $ (3,538 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 126,624 92,587 Net loss per share of common stock, basic and diluted $ (0.04 ) $ (0.04 ) The following table sets forth the weighted average number of potential common shares excluded from the calculation of net loss per diluted share, because including them would be anti-dilutive: Three Months Ended March 31, 2022 2021 Options to purchase common stock 11,089 7,067 Series B convertible preferred stock 165 177 Warrants to purchase common stock 22,277 25,078 33,531 32,322

Note 11 - Income Taxes

Note 11 - Income Taxes	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 11: Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not As a result of the Company’s cumulative losses, management has concluded that a full valuation allowance against the Company’s net deferred tax assets is appropriate. No March 31, 2022 December 31, 2021,

Note 12 - Concentration of Cred

Note 12 - Concentration of Credit Risk	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	NOTE 12: Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits which include a money market account. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250. March 31, 2022 December 31, 2021,

Note 13 - Commitments and Conti

Note 13 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 13: Lease Commitments The Company evaluates all contractual agreements at inception to determine if they contain a lease. Lease liabilities are measured at present value of lease payments not 12 no Our office lease expired February 28, 2022. March 2022, 12 three March 31, 2022, 2021, March 31, 2022, December 31, 2021, $0 Litigation and Contingencies We are subject to legal proceedings and claims that arise in the normal course of business. We believe these matters are either without merit or of a kind that should not

Note 14 - Stock Based Compensat

Note 14 - Stock Based Compensation	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	NOTE 14: Stock Option and Incentive Plan On March 24, 2020, 2020 2020 No may 2020 10 2020 May 14, 2021, 2020 2020 March 31, 2022. The Company granted options to purchase 2,722 and 0 shares of common stock to employees during the three March 31, 2022 2021, three March 31, 2022 three March 31, 2022 2021. The fair value of stock options granted for the three March 31, 2022, Three Months Ended March 31, 2022 Risk-free interest rate 1.86% 2.53% Expected term (in years) 5.51 - 6.11 Dividend yield - Expected volatility 117% 128% Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of $1,806 and $640 for the three March 31, 2022 2021, Three Months Ended March 31, 2022 2021 General and administrative $ 1,184 $ 450 Research and development 622 190 Total stock compensation expense $ 1,806 $ 640 Options issued and outstanding as of March 31, 2022, three Number of Underlying Shares Weighted- Average Exercise Price Per Share Weighted- Average Contractual Life Remaining in Years Aggregate Intrinsic Value Outstanding as of January 1, 2022 10,027 $ 2.82 $ 1,006 Granted 2,722 1.25 Exercised - - Forfeited - - Expired - - Outstanding as of March 31, 2022 12,749 2.48 8.42 $ - Exercisable as of March 31, 2022 7,279 2.82 7.67 Vested and expected to vest 12,749 $ 2.48 8.42 $ - At March 31, 2022, Defined Contribution Plan The Company has a defined contribution plan to which employees of the Company may may 6%. three March 31, 2022 2021,

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions to Form 10 10 01 X. not no 10 December 31, 2021. not In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three March 31, 2022, not may December 31, 2022.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Segment Reporting, Policy [Policy Text Block]	Segments The Company operates in a single segment. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. To date, our chief operating decision maker has made such decisions and assessed performance at the company level as one segment.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development (R&D) costs are generally expensed as incurred. R&D expenses include, for example, manufacturing expense for the Company's drugs under development, expenses associated with clinical trials and associated salaries and benefits. The Company has entered into various research and development contracts with research institutions, clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may may R&D expenses also include an allocation of the CEO's salary and related benefits including bonus and non-cash stock-based compensation expense based on an estimate of total hours expended on research and development activities. The Company's CEO is involved in the development of the Company's drug candidates and oversight of the related clinical trial activity.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements The Company records financial assets and liabilities measured on a recurring and non-recurring basis as well as all non-financial assets and liabilities subject to fair value measurement at the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. These fair value principles prioritize valuation inputs across three 1 2 3 8.
Share-Based Payment Arrangement [Policy Text Block]	Stock-based Payments The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including employee stock options. Stock compensation expense is based on the estimated grant date fair value and is recognized as an expense over the requisite service period. The Company has made a policy election to recognize forfeitures when they occur. The fair value of each option grant is estimated using the Black-Scholes option-pricing model, which requires assumptions regarding the expected volatility of the stock options, the expected life of the options, an expectation regarding future dividends on the Company’s common stock, and estimation of an appropriate risk-free interest rate. The Company’s expected common stock price volatility assumption is based upon the historical volatility of our stock price. The Company has elected the simplified method for the expected life assumption for stock option grants, which averages the contractual term of the options of ten one four not no
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements On May 3, 2021, No. 2021 04, Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options no March 31, 2022, not On January 1, 2022, 2021 10 Annual Disclosure Requirements for Business Entities Receiving Government Assistance. (Topic 832 Disclosures by Business Entities about Government Assistance 6.

Note 5 - Prepaid Expenses (Tabl

Note 5 - Prepaid Expenses (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	As of March 31, As of December 31, 2022 2021 Prepaid research and development $ 2,927 $ 1,853 Prepaid insurance 613 461 Professional services 293 124 Other 41 50 Total prepaid expenses $ 3,874 $ 2,488

Note 7 - Payroll Liabilities (T

Note 7 - Payroll Liabilities (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	March 31, December 31, 2022 2021 Accrued bonuses $ 241 $ 894 Accrued vacation 229 183 Accrued payroll 123 107 Total payroll liabilities $ 593 $ 1,184

Note 8 - Fair Value of Financ_2

Note 8 - Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	March 31, 2022 Estimated Fair Value Level 1 Level 2 Level 3 Assets: Money market account $ 51,797 $ 51,797 $ - $ - December 31, 2021 Estimated Fair Value Level 1 Level 2 Level 3 Assets: Money market account $ 51,796 $ 51,796 $ - $ -
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Warrant liability Beginning balance $ 13,003 Reclassification of equity upon adoption of accounting standard (13,003 ) Issuance of warrants - Change in fair value - Ending balance $ -

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Outstanding Warrants to Purchase Shares Exercise Price Per Share Expiration date May 2018 warrants 762 $ 4.05 May 30, 2022 December 2020 warrants 6,490 $ 1.00 December 11 2024-June 21, 2025 January 2021 warrants 4,500 $ 1.055 July 8, 2025 March 2021 warrants 10,525 $ 2.88 September 22, 2025 22,277

Note 10 - Net Loss Per Share (T

Note 10 - Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 31, 2022 2021 Numerator Net loss attributable to common shareholders $ (4,786 ) $ (3,538 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 126,624 92,587 Net loss per share of common stock, basic and diluted $ (0.04 ) $ (0.04 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended March 31, 2022 2021 Options to purchase common stock 11,089 7,067 Series B convertible preferred stock 165 177 Warrants to purchase common stock 22,277 25,078 33,531 32,322

Note 14 - Stock Based Compens_2

Note 14 - Stock Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended March 31, 2022 Risk-free interest rate 1.86% 2.53% Expected term (in years) 5.51 - 6.11 Dividend yield - Expected volatility 117% 128%
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Number of Underlying Shares Weighted- Average Exercise Price Per Share Weighted- Average Contractual Life Remaining in Years Aggregate Intrinsic Value Outstanding as of January 1, 2022 10,027 $ 2.82 $ 1,006 Granted 2,722 1.25 Exercised - - Forfeited - - Expired - - Outstanding as of March 31, 2022 12,749 2.48 8.42 $ - Exercisable as of March 31, 2022 7,279 2.82 7.67 Vested and expected to vest 12,749 $ 2.48 8.42 $ -
Share-Based Payment Arrangement, Option [Member]
Notes Tables
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended March 31, 2022 2021 General and administrative $ 1,184 $ 450 Research and development 622 190 Total stock compensation expense $ 1,806 $ 640

Note 2 - Liquidity and Capita_2

Note 2 - Liquidity and Capital Resources (Details Textual) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Net Income (Loss) Attributable to Parent, Total	$ (4,786)	$ (3,538)
Net Cash Provided by (Used in) Operating Activities, Total	(4,878)	(4,408)
Cash and Cash Equivalents, at Carrying Value, Total	131,486	$ 137,574	$ 136,377
Working Capital (Deficit)	$ 134,526
Proceeds from Issuance or Sale of Equity, Total			$ 113,486

Note 3 - Summary of Accountin_2

Note 3 - Summary of Accounting Policies (Details Textual)	3 Months Ended
	Mar. 31, 2022
Number of Operating Segments	1
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Vesting Term (Year)	4 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Vesting Term (Year)	1 year

Note 4 - Restricted Cash (Detai

Note 4 - Restricted Cash (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021
Restricted Cash and Cash Equivalents, Total	$ 110	$ 110	$ 110

Note 5 - Prepaid Expenses - Sch

Note 5 - Prepaid Expenses - Schedule of Prepaid Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Prepaid research and development	$ 2,927	$ 1,853
Prepaid insurance	613	461
Professional services	293	124
Other	41	50
Total prepaid expenses	$ 3,874	$ 2,488

Note 6 - Research and Develop_2

Note 6 - Research and Development Rebate Receivable (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Research and Development Expense, Total	$ 1,499	$ 1,379
Research and Development Tax Rebate Receivable	668		$ 1,072
Other Income [Member]
Foreign Currency Transaction Gain (Loss), Realized	28	6
Atossa Genetics AUS Pty Ltd [Member]
Research and Development Expense, Total	354	270
Research and Development Cash Rebate	563		0
Research and Development Tax Rebate Receivable	668		$ 1,072
Research and Development Expense, Reduced Amount Due to Tax Rebate	$ 140	$ 107

Note 7 - Payroll Liabilities -

Note 7 - Payroll Liabilities - Schedule of Payroll Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Accrued bonuses	$ 241	$ 894
Accrued vacation	229	183
Accrued payroll	123	107
Total payroll liabilities	$ 593	$ 1,184

Note 8 - Fair Value of Financ_3

Note 8 - Fair Value of Financial Instruments (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Jan. 01, 2021	Dec. 31, 2020
Stockholders' Equity Attributable to Parent, Ending Balance	$ 135,156	$ 138,136	$ 139,701		$ 27,168
Accounting Standards Update 2020-06 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]
Stockholders' Equity Attributable to Parent, Ending Balance				$ 13,003

Note 8 - Fair Value of Financ_4

Note 8 - Fair Value of Financial Instruments - Assets and Liabilities Measured on Recurring Basis (Details) - Fair Value, Recurring [Member] - Money Market Funds [Member] - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Money market account	$ 51,797	$ 51,796
Fair Value, Inputs, Level 1 [Member]
Money market account	51,797	51,796
Fair Value, Inputs, Level 2 [Member]
Money market account	0	0
Fair Value, Inputs, Level 3 [Member]
Money market account	$ 0	$ 0

Note 8 - Fair Value of Financ_5

Note 8 - Fair Value of Financial Instruments - Changes in Warrant Liability (Details) - Warrant Liability [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Beginning balance	$ 13,003
Reclassification of equity upon adoption of accounting standard	(13,003)
Issuance of warrants	0
Change in fair value	0
Ending balance	$ 0

Note 9 - Stockholders' Equity_2

Note 9 - Stockholders' Equity (Details Textual) - USD ($)	Mar. 22, 2021	Jan. 08, 2021	Jan. 06, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 21, 2020	Dec. 17, 2020
Number of Shares Authorized to Issue (in shares)				185,000,000
Common Stock, Shares Authorized (in shares)				175,000,000		175,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.18		$ 0.18
Preferred Stock, Shares Authorized (in shares)				10,000,000		10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.001		$ 0.001
Preferred Stock, Shares Issued (in shares)				1,000		1,000
Consummate a Business Combination, Percentage of Acquired Outstanding Shares				50.00%
Consummate a Business Combination, Percentage of Aggregate Ordinary Voting Power				50.00%
Class of Warrant or Right, Outstanding (in shares)				22,277,000
Class of Warrant or Right, Exercised During Period (in shares)				0	32,063,000
Proceeds from Warrant Exercises				$ 0	$ 32,760,000
Stock Issued During Period, Shares, Warrant Exercised (in shares)					32,063,000
Conversion of Series B Convertible Preferred Stock into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)				0	1
Conversion of Stock, Shares Issued (in shares)					285
The 2021 Financing Transaction Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	0.75					1
Warrants and Rights Outstanding, Term (Year)	4 years 6 months
Shares Issuable Upon Exercise of Warrants (in shares)	13,021,000
Warrants Associated with 2020 Offering Consisting of Common Stock and Warrants [Member] | Minimum [Member]
Warrants and Rights Outstanding, Term (Year)								4 years
Warrants Associated with 2020 Offering Consisting of Common Stock and Warrants [Member] | Maximum [Member]
Warrants and Rights Outstanding, Term (Year)								4 years 6 months
The 2020 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)							1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 1
Warrants Exercisable, Ownership Percentage of Company’s Shares Allowed							4.99%
Common Stock, Convertible, Ownership Percentage of Company’s Shares Allowed							9.99%
Class of Warrant or Right, Outstanding (in shares)				6,490,000
The 2021 Financing Transaction [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.18		$ 0.18
Stock Issued During Period, Shares, New Issues (in shares)	17,361,000		23,850,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	13,021,000
Issuance of Common Stock and Warrants, Combined Purchase Price Per Share (in dollars per share)			$ 1.055
Proceeds From Issuance of Common Stock and Warrants, Net of Issuance Costs	$ 46,400,000	$ 23,300,000
Shares Issued, Price Per Share (in dollars per share)	$ 2.88
The 2021 Financing Transaction [Member] | The 2021 Financing Transaction Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			17,888,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)			0.75
Warrants and Rights Outstanding, Term (Year)			4 years 6 months
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 1.055
Series A Junior Participating Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)				750,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.001
Preferred Stock, Shares Issued (in shares)				0		0
Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)				4,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.001
Preferred Stock, Shares Issued (in shares)				0		0
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)				25,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.001
Stated Value per Share				$ 1,000
Preferred Stock, Convertible, Conversion Price (in dollars per share)				$ 3.52
Preferred Stock, Convertible, Ownership Percentage of Company’s Shares Allowed				9.99%
Series C Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)				20,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.001
Preferred Stock, Shares Issued (in shares)				0		0

Note 9 - Stockholders' Equity -

Note 9 - Stockholders' Equity - Outstanding Warrants (Details) shares in Thousands	Mar. 31, 2022$ / sharesshares
Outstanding Warrants to Purchase Shares (in shares)	22,277
The 2018 Warrants [Member]
Outstanding Warrants to Purchase Shares (in shares)	762
Exercise Price (in dollars per share) | $ / shares	$ 4.05
The 2020 Warrants [Member]
Outstanding Warrants to Purchase Shares (in shares)	6,490
Exercise Price (in dollars per share) | $ / shares	$ 1
The January 2021 Warrants [Member]
Outstanding Warrants to Purchase Shares (in shares)	4,500
Exercise Price (in dollars per share) | $ / shares	$ 1.055
The March 2021 Warrants [Member]
Outstanding Warrants to Purchase Shares (in shares)	10,525
Exercise Price (in dollars per share) | $ / shares	$ 2.88

Note 10 - Net Loss Per Share -

Note 10 - Net Loss Per Share - Schedule of Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Net loss attributable to common shareholders	$ (4,786)	$ (3,538)
Weighted average common shares outstanding used to compute net loss per share, basic and diluted (in shares)	126,624	92,587
Net loss per share of common stock, basic and diluted (in dollars per share)	$ (0.04)	$ (0.04)

Note 10 - Net Loss Per Share _2

Note 10 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Number of potential common shares excluded (in shares)	33,531	32,322
Share-Based Payment Arrangement, Option [Member]
Number of potential common shares excluded (in shares)	11,089	7,067
Series B Convertible Preferred Stock [Member]
Number of potential common shares excluded (in shares)	165	177
Warrant [Member]
Number of potential common shares excluded (in shares)	22,277	25,078

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Income Tax Expense (Benefit), Total	$ 0	$ 0	$ 0

Note 12 - Concentration of Cr_2

Note 12 - Concentration of Credit Risk (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Cash, Uninsured Amount	$ 131,279	$ 136,185

Note 13 - Commitments and Con_2

Note 13 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Lessee, Operating Lease, Monthly Rent Payments	$ 1
Operating Lease, Expense	8	$ 5
Operating Lease, Liability, Total	0		$ 0
Operating Lease, Right-of-Use Asset	$ 0		$ 0

Note 14 - Stock Based Compens_3

Note 14 - Stock Based Compensation (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	May 14, 2021	Mar. 31, 2022	Mar. 31, 2021	Mar. 24, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)		2,722
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)
Share-Based Payment Arrangement, Expense		$ 1,806	$ 640
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares, Ending Balance (in shares)		5,470
Defined Contribution Plan, Employer Matching Contribution, Percent of Match		6.00%
Defined Contribution Plan, Cost		$ 34	$ 33
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount		$ 8,279
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		1 year 5 months 23 days
The 2020 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)				3,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)	15,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)		2,722	0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)		$ 1.07
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)		0	0
The 2020 Stock Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)		9,214
Share-Based Payment Arrangement, Expense		$ 1,806	$ 640

Note 14 - Stock Based Compens_4

Note 14 - Stock Based Compensation - Valuation Assumptions (Details)	3 Months Ended
	Mar. 31, 2022
Dividend yield	0.00%
Share-Based Payment Arrangement, Option [Member]
Dividend yield
Share-Based Payment Arrangement, Option [Member] | Minimum [Member]
Risk-free interest rate	1.86%
Expected term (in years) (Year)	5 years 6 months 3 days
Expected volatility	117.00%
Share-Based Payment Arrangement, Option [Member] | Maximum [Member]
Risk-free interest rate	2.53%
Expected term (in years) (Year)	6 years 1 month 9 days
Expected volatility	128.00%

Note 14 - Stock Based Compens_5

Note 14 - Stock Based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Stock compensation expense	$ 1,806	$ 640
General and Administrative Expense [Member]
Stock compensation expense	1,184	450
Research and Development Expense [Member]
Stock compensation expense	$ 622	$ 190

Note 14 - Stock Based Compens_6

Note 14 - Stock Based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Outstanding, shares (in shares)	10,027
Outstanding, weighted average exercise price per share (in dollars per share)	$ 2.82
Outstanding, aggregate intrinsic value	$ 0	$ 1,006
Granted (in shares)	2,722
Granted, weighted average exercise price per share (in dollars per share)	$ 1.25
Granted, aggregate intrinsic value
Exercised (in shares)
Exercised, weighted average exercise price per share (in dollars per share)
Exercised, aggregate intrinsic value
Forfeited (in shares)
Forfeited, weighted average exercise price per share (in dollars per share)
Expired (in shares)
Expired, weighted average exercise price per share (in dollars per share)
Outstanding, shares (in shares)	12,749
Outstanding, weighted average exercise price per share (in dollars per share)	$ 2.48
Outstanding, weighted average contractual life remaining in years (Year)	8 years 5 months 1 day
Exercisable, shares (in shares)	7,279
Exercisable, Weighted average exercise price per share (in dollars per share)	$ 2.82
Exercisable, weighted average contractual life remaining in years (Year)	7 years 8 months 1 day
Exercisable, aggregate intrinsic value
Vested and expected to vest, shares (in shares)	12,749
Vested and expected to vest, Weighted average exercise price per share (in dollars per share)	$ 2.48
Vested and expected to vest, weighted average contractual life remaining in years (Year)	8 years 5 months 1 day
Vested and expected to vest, aggregate intrinsic value	$ 0